This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Neurocrine Biosciences' Management Presents At Morgan Stanley Global Healthcare Conference - Transcript

Stocks in this article: NBIX

Neurocrine Biosciences, Inc. (NBIX)

Morgan Stanley Global Healthcare Conference Call

September 12, 2012 08:00 AM ET

Executives

Kevin C. Gorman - President, CEO

Analysts

Presentation

Question-and-Answer Session

Unidentified Analyst

It is my pleasure to introduce Kevin Gorman, President and CEO of Neurocrine Biosciences. And I think just to start, if you can give us a brief overview of what you guys have going on currently?

Kevin C. Gorman

Sure, [Sarah]. Thank you very much and thank you to Morgan Stanley for the opportunity to come today and speak. I will be making forward-looking statements throughout this Q&A. So, I would like you to – direct you to our recent SEC filings for all the risk factors associated with that. Neurocrine Biosciences is a neuroendocrine Company. We have two main programs that are going on in the Company today and I think that most of our questions are going to center around that and I do look forward to taking any questions that you all might have. The first program is our GnRH program. The lead compound is called Elagolix. It’s partnered with Abbott Pharmaceuticals. Abbott has the drug in the Phase 3 trial for endometriosis and they have it in a Phase 2 proof-of-concept trial ongoing in uterine fibroids.

This is a program that was discovered at Neurocrine approximately 11 years ago and we formed a relationship with Abbott approximately 2.5 years ago. The second program which was wholly owned by Neurocrine and again completely all the discovery was done at Neurocrine starting about five years ago is a VMAT2 inhibitor. VMAT2 is a presynaptic target, Vesicular Mono-Amine Transporter and we have this – currently we’re going to be starting Phase 2b study in Tardive Dyskinesia and Tardive Dyskinesia is a movement disorder that is caused by antipsychotic drugs.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,827.75 +12.81 0.07%
S&P 500 2,072.83 +5.80 0.28%
NASDAQ 4,787.3170 +29.0650 0.61%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs